The Milner Therapeutics Institute has added Pfizer as a partner to the Milner Therapeutics Consortium. Dr Ron Newbold, Vice President, External R&D Innovation at Pfizer, will join the Milner Innovation Board alongside representatives from Astex, AstraZeneca, GlaxoSmithKline, Shionogi, MedImmune, University of Cambridge, Babraham Institute and Sanger Institute.
The Consortium acts as a ‘matchmaking’ service between pharmaceutical companies and researchers and allocates funds for partnering opportunities in Cambridge. It has been specifically modelled to help facilitate the speedy exchange of resources and information between partners through a pre-signed agreement.
Company partners are able to work individually with academics or through joint activities in order to help to accelerate drug development. The Consortium’s Innovation Board includes companies and academic partners and is responsible for overseeing the strategic direction, collective research funding and collaborative activities.
Professor Tony Kouzarides, founder and director of the Milner Therapeutics Institute, said: “We are delighted that Pfizer has joined the Consortium to develop mutually beneficial collaborations with Cambridge academics and the Milner Therapeutics Institute. We are focussed on working with Pfizer to advance disease understanding and make a difference to therapies in the clinic.”
Dr Ron Newbold said: “The UK has a very strong academic and biotech community, and we anticipate working with many world-class scientists that will be supported and inspired by the work of the Milner Institute in the coming years.”